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Introduction
Large-scale expression analysis of mRNA has proven a
powerful tool for morphological classification of tumours of
the breast [1] as well as for prediction of disease outcome
[2,3]. Expression studies of tens of thousands of tran-
scripts give exciting possibilities to draw molecular por-
traits of tumours [1] within a given range of expression
levels, but are less informative for the absolute amounts of
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Abstract
Introduction The expression of the oestrogen receptor (ER) is
one of the more important clinical parameters of breast cancer.
However, the relationship between the ER and its ligand,
oestradiol, and the enzymes that synthesise it are not well
understood. The expression of mRNA transcripts of members
of the oestradiol metabolic and signalling pathways including
the ER was studied in detail.
Method mRNA transcripts for aromatase (CYP19), 17-
β-hydroxysteroid dehydrogenase I, 17-β-hydroxysteroid dehydro-
genase II, ERα, ERβ, steroid sulfatase (STS), oestradiol
sulfotransferase (EST), cyclin D1 (CYCLD1) and ERBB2 were
fluorometrically quantified by competitive RT-PCR using an
internal standard in 155 breast carcinomas. In addition, the
transcripts of CYP19 were analysed for alternative
splicing/usage of exon 1 and an alternative poly A tail.
Results A great variability of expression was observed, ranging
from 0 to 2376amol/mg RNA. The highest levels were observed
for STS and EST, and the lowest levels (close to zero) were
observed for the 17-β-hydroxysteroid dehydrogenase iso-
enzymes. The levels of mRNA expression were analysed with
respect to clinical and histopathological parameters as well as
for disease-free survival. High correlation of the mRNA
expression of STS, EST and 17-β-hydroxysteroid dehydrogenase
in the tumours suggested a common regulation, possibly by their
common metabolite (oestradiol). Hierarchical clustering analysis
in the 155 patients resulted in two main clusters, representing
the ERα-negative and ERα-positive breast cancer cases. The
mRNA expression of the oestradiol metabolising enzymes did not
follow the expression of the ERα in all cases, leading to the
formation of several subclasses of tumours. Patients with no
expression of CYP19 and patients with high levels of expression
of STS had significantly shorter disease-free survival time
(P > 0.0005 and P < 0.03, respectively). Expression of ERβ
mRNA was a better prognostic factor than that of ERα in this
material.
Conclusion Our results indicate the importance of CYP19 and
the enzymes regulating the oestrone sulfate metabolism as
factors of disease-free survival in breast cancer, in addition to
the well-known factors ER and ERBB2.
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single transcripts. At the same time, intratumoural mRNA
expression of enzymes involved in the oestradiol metabo-
lism has been studied in separate reports on different
materials for single genes such as aromatase (CYP19)
[4], steroid sulfatase (STS) [5] and 17-β-hydroxysteroid
dehydrogenase I (HSD1) [6]. It is difficult, however, to see
how these genes are expressed in concert. In the present
article, we attempt to quantify the mRNA expression of a
number of genes in the oestradiol pathway (Fig. 1) simulta-
neously by fluorimetric quantitation of RT-PCR using
gene-specific internal RNA standards.
Aromatase (CYP19, 15q21) is a key enzyme of the
pathway (Fig. 1) and its activity determines the local
oestrogen level. Aromatase expression has been sug-
gested to play a role in neoplastic proliferation in both
human breast and endometrial carcinomas [7]. Tissue-
specific regulation of expression has been studied by
several groups, and a switch from an adipose-specific
exon 1 (exon 1b or exon I.4) promoter used in nontumour
breast tissues to the ovary-specific exon 1 (exon 1c or
exon I.2) has been observed in breast cancer tissue [8,9].
Our previous data show that the alternative switch from
the usual adipose tissue promoter to an apparently
stronger ‘ovary’ promoter correlates significantly to the
CYP19 mRNA expression level (P < 0.001) [4]. Toda and
colleagues described alternative RNA processing using
different poly A signals of aromatase mRNA in human pla-
centa [10]. In the current investigation, we looked for such
poly A variants in breast carcinomas.
HSD1 (17q) catalyses the final conversion of oestrone to
oestradiol (Fig.1). The reverse inactivation of the oestro-
genic 17-β-oestradiol to oestrone is catalysed by
17β-hydroxysteroid-dehydrogenase II (HSD2) (6q24) in the
human breast as well as in the endometrium [11,12]. Since
oestradiol is the most potent oestrogenic end product and
since this reaction finalises several pathways by which
oestrone can be created, a possible difference in the activity
of the enzyme could be of importance for oestrogen levels.
Sulfatation, catalysed by oestradiol sulfotransferase (EST),
is an important pathway in the biotransformation of steroid
hormones. Oestrone sulfate is the predominant form of
oestrogen found in the circulation in women and could
thus serve as a precursor for active oestrogens in target
tissues by removal of the sulfate group through the action
of endogenous STS [13,14].
Two isoforms of the human oestrogen receptor (ER)
occur, ERα and ERβ, each with distinct tissue and cell
patterns of expression (reviewed in [15]). Oestrogen
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Figure 1
Oestradiol synthesis pathway from cholesterol. The present study was focused on the right branch of this panel – the final metabolism of oestradiol
from androsenedione. Thick arrows indicate the enzymes and activities coded by the mRNA transcripts studied in the present report.
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binds to the ER, which modulates the transcription of a
series of genes, including genes coding for a number of
growth factors such as insulin-like growth factor 1 and
transforming growth factor alpha [16,17]. These genes
are part of the main gene cluster that defines the group to
the luminal subtype A and subtype B breast carcinomas
[1]. Oestrogen has been shown to cause upregulation of
oncogenes such as c-myc through binding to its receptor,
and through the Src/p21ras/mitogen-activated protein
kinase pathway of c-fos and c-jun, leading to stimulation of
breast cancer cell proliferation [18]. Oestradiol has
recently been shown to modulate breast cancer cell apop-
tosis [19], while androgens have been shown to downreg-
ulate bcl-2 protooncogene expression, providing an
alternative mechanism for their inhibitory effect on breast
cancer cell growth [20]. ERβ has been measurable in
normal breast tissue but was very low in breast carcino-
mas, suggesting that ERβ might control the ERα-mediated
mitogenic activity of oestrogens [21]. Numerous splice
variants of ERβ have also been described.
Additional proteins under growth factor regulation, includ-
ing the cell cycle protein cyclin D1 and ligands for the
human epidermal receptor (HER) family, have been shown
to interact with the oestrogen receptor either by direct
binding or by recruiting co-activators of the SRC-1 family
to the ER in the absence of oestrogen itself [22,23].
In the present article, we report a high-precision mRNA
expression profile of the genes coding for the enzymes
metabolising oestradiol, or coding for its most important
receptors ERα and ERβ, as well as modifiers of hormonal
response such as cyclin D1 and HER-2, coded by ERBB2
(Fig.1, thick arrows) from the same tumours. Internal stan-
dards were constructed by insertion of 20–30bp fragments
into in vitro synthesised transcripts for every gene: aro-
matase (CYP19), HSD1, HSD2, ERα, ERβ, STS and EST.
To examine additional factors of ER regulation, independent
of the presence of oestrogen, we included into our analysis
cyclin D1 (CYCLD1) and ERBB2. These well-characterised
prognostic factors of breast cancer are known to activate
the ER or be activated by the ER [24,25].
Materials and methods
Immunohistochemistry
Frozen sections were prepared from fresh tumour tissue
and immunostaining for ER protein was performed, applying
the avidin–biotin peroxidase complex method. The antibod-
ies were from DAKO (batch M7047; DakoCytomation, Inc.
Carpinteria, CA, USA). All series included positive and neg-
ative controls. Only cells with nuclear staining were scored
as positive. The number of immunopositive cells was semi-
quantitatively estimated: grade +, 5–10% positive cells;
grade ++, 11–50% positive cells; and grade +++, > 50%
positive cells. For each sample at least 100, usually more
than 1000, tumour cells were analysed.
RNA was prepared from fresh frozen tumours from a con-
secutive series of 155 breast cancer patients admitted to
the City Hospital of Oslo with a mean age at diagnosis of
65 years (range 28–87 years). The samples were col-
lected in the period 1989–1993 and the ethical proce-
dures followed the present day standard. A letter to the
patients asking them to donate blood and a tumour speci-
men was sent, and those patients who consented partici-
pated in the study.
Tumour status and lymph node status were characterised
based on the pathology reports according to the 1988
tumour node metastasis classification. Fresh frozen
tumour tissue (20–50 mg) was dissected and powdered
in liquid nitrogen in steel mortars. The powder was then
immediately (while still frozen) transferred to 2 ml screw-
capped tubes with 0.5 ml Trisol TM (Gibco-BRL, Grand
Island, NY, USA). Total RNA was prepared by standard
procedures using isopropanol precipitation. Fluorometric
quantitation was performed to determine the absolute
mRNA contents using fluorescent dye-labelled primers in
the presence of an internal standard for each gene:
CYP19, HSD1, HSD2, ERα, ERβ, STS, EST (SULT1A3),
cyclin D1, ErbB2 and β-actin. To prepare the internal stan-
dard RNA, the modified cDNAs for each gene were con-
structed by inserting 20–30 bp DNA fragments between
the two PCR primer sites. The internal standard RNAs
were synthesised in vitro with T7 RNA polymerase using
the modified cDNA as templates. Total RNAs mixed with a
known amount of internal standard RNAs were subjected
to reverse transcription with RAV-2 transcriptase (Takara
Shuzo Co., Kyoto, Japan) and a gene-specific amplifica-
tion at 42°C for 40 min. The resulting cDNAs were ampli-
fied by PCR using fluorescence-labelled (FAM; Perkin
Elmer Co., Foster City, CA, USA), gene-specific, sense
primers. Fluorescent PCR products were electrophoresed
in a 2% agarose gel and were analysed with a Gene
Skanner 362 Fluorescence Fragment Analyzer (ABI;
Perkin Elmer Co.). The amount of aromatase mRNA was
calculated from the peak areas of the fluorescent products
by the internal standard method and was corrected on the
basis of β-actin mRNA.
Alternative exon 1 of aromatase
The utilisation of alternative exons 1 of the aromatase gene
was investigated by RT-PCR using sense primers specific
for exons 1a, 1b, 1c, 1d and a fluorescent dye (FAM)-
labelled antisense primer specific for exon 3, according to
the previously described protocol [26].
Alternative poly A tail of aromatase
One common fluorescent-labelled primer (5′-FAM AGC
AAC ATT CAT AGT CTT TG) and the poly A-specific
primers 5′-CCA CAC TAA TTG AGC TAA GC-3′ (long
transcript) and an equimolar mix of 5′-(T)15GAACA-3′ and
5′-(T)15GGGAA-3′ (short transcript) were used to simulta-
neously amplify two different RT PCR products with length
352 bp and 422 bp, respectively. cDNA derived from the
variant short transcript [27] inserted at an EcoRI site in a
pUC118 vector was used as the positive control for ampli-
fying the alternative poly A site.
Statistical analysis
Clinical parameters as well as mRNA levels and data on
alternative splicing were collected in a SPSS file (SPSS
Inc., Chicago, IL, USA), where the initial descriptive statis-
tics, cross tab (chi-square test) and Pearson correlation
analysis were performed. Survival analysis was performed
using Kaplan–Meier plots in SPSS with log-rank statistics.
The follow-up interval was 12 years (around 140 months;
the disease-free survival was in months to first recurrence,
the longest being 111 months). Patients were under
observation every 6 months for the first 5 years, then once
a year for the next 2–3 years. After that the information
about the patients’ status was collected in the Cancer
Registry of Norway and updated every year. Hierarchical
clustering and visualisation were performed using
EPCLUST (http://ep.ebi.ac.uk/ep/epclust/). mRNA levels
were calculated relative to the median, and clustering
analysis of levels above/below the median was performed.
Results
mRNA expression
Competitive RT-PCR was used to quantify the amounts of
mRNA of nine different transcripts as well as β-actin in
breast carcinomas. In the series of 155 tumour samples
two independent quantitations from the same mRNA
preparations were performed for CYP19 (aromatase),
giving a correlation of r = 0.811 (P < 0.0001). Quantitation
of mRNA of the ERα by competitive RT-PCR was in con-
cordance with the immunohistochemistry data for total
ERα protein (P < 0.0001). The absolute amount of each of
the studied transcripts (amol/mg RNA) gave a high corre-
lation to that adjusted by β-actin, suggesting a uniformity
of the samples and the mRNA preparation procedures. A
great variability of expression among the patients was
observed, ranging from 0 to 2376 amol/mg RNA, with the
highest levels being observed for STS and EST, and the
lowest levels (close to zero) observed for both HSD isoen-
zymes (Table 1).
Correlations of expression levels of the various transcripts
were studied using Pearson correlation (Table 2). A high
correlation was observed between the expression of EST
and STS (r = 0.252, P < 002). While the levels of EST cor-
related with those of ERα (r = 0,550, P < 0.0001), the
levels of STS correlated with ERβ (r = 274, P < 0.001).
Expression of HSD1 mRNA levels also correlated with
both EST and STS mRNA expression (P < 0.003 and
P < 0.0001, respectively). Furthermore, mRNA levels were
calculated as relative to the median and clustering analysis
of levels above/below the median was performed (Fig. 2).
Two distinct clusters of the ER-positive and ER-negative
samples were observed. The mRNA expression of the
oestradiol metabolising enzymes, however, did not follow
the expression of the ER in all cases, leading to the forma-
tion of several subclasses of tumours. Cyclin D1 fell into
the same cluster together with EST and ERα
(P < 0.0001).
mRNA expression and clinical and histopathological
parameters
Expression of mRNA was then studied in relation to differ-
ent clinical and histopathological parameters: tumour size
(tumor category [TKAT]), lymph node status, distant
metastases, stage of disease, site, and histological type
(Table 3). Data were analysed in two ways using the
SPSS data editor: by comparing the levels of the different
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R49
Table 1
Descriptive statistics of mRNA expression of oestrogen metabolising enzymes (amol/mg RNA) in the tumours of a set of 155
breast cancer patients
Transcript Mean Median Minimum Maximum Standard deviation
Aromatase (CYP19) 59.24 12.2 0.00 750.00 13.92
17β-Hydroxysteroid dehydrogenase I 0 0.0 0.00 0.95 0.10
17β-Hydroxysteroid dehydrogenase II 0 0.0 0.00 0.27 0.00
Oestrogen receptor α 4.31 1.2 0.00 29.50 6.20
Oestrogen receptor β 0.16 0.0 0.00 2.33 0.28
Steroid sulfatase 335.09 204.5 0.00 2376.34 391.18
Oestradiol sulfotransferase 124.49 104.6 0.00 436.00 94.34
Cyclin D1 0.46 0.2 0.00 4.73 0.68
ERBB2 0.38 0.0 0.00 7.23 1.10
transcripts between the different clinical categories using
box plots, and by categorising these levels into two cate-
gories (below and above the median) or into quartiles and
comparing their distribution among the clinical categories
using cross tabs. mRNA levels of STS and EST were sig-
nificantly higher in patients with TKAT 3 and TKAT 4 than
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Table 2
Pearson correlation of the expression levels of mRNA coding for oestradiol metabolising enzymes
CYP19 STS HSD1 HSD2 EST ERα ERβ ERBB2 Cyclin D1
CYP19 1 0.081 –0.051 –0.054 0.021 –0.057 0.065 –0.071 –0.047
STS 1 0.333** 0.027 0.252** 0.045 0.274** 0.215** 0.195*
HSD1 1 –0.051 0.242** 0.107 0.047 0.003 0.164*
HSD2 1 –0.065 –0.144 0.050 –0.022 0.000
EST 1 0.550** –0.082 0.089 0.422**
ERα 1 –0.089 –0.104 0.502**
ERβ 1 –0.031 –0.029
ERBB2 1 0.010
Cyclin D1 1
Data presented as significance (two-tailed). CYP19, aromatase; STS, steroid sulfatase; HSD1, 17β-hydroxysteroid dehydrogenase I; HSD2, 17β-
hydroxysteroid dehydrogenase II; EST, oestradiol sulfotransferase; ERα, oestrogen receptor α; ERβ, oestrogen receptor β. *Correlation significant
at the 0.05 level (two-tailed). **Correlation significant at the 0.01 level (two-tailed).
Table 3
Mean values of mRNA expression of oestrogen metabolising enzymes (amol/mg RNA) in relation to the clinical and
histopathological parameters of a set of 155 breast cancer patients
Clinical parameter n CYP19 STS HSD1 HSD2 EST ERα ERβ
Age
< 50 years 48 37.60 316.3 0.0027 0.0250 140.49 2.20 0.22
> 50 years 107 84.30 347.3 0.0198 0.0080 100.28 4.96 0.14
Stage
I 81 77.50 265.7 0.0136 0.0970 93.81 4.60 0.20
II 57 45.90 304.5 0.2580 0.1170 135.22 4.70 0.16
III 17 13.60 382.1* 0.0970 – 122.98 2.04 0.13
Tumour category
1 61 73.30 285.3 0.0140 0.0120 98.30 4.20 1.19
2 55 67.80 223.7 0.0273 0.1090 113.30 4.70 0.16
3 29 14.30 409.1 0.0090 – 139.20 3.60 0.15
4 10 6.3*** 446.3** 0.0140 – 194.8*** 2.70 0.04
Lymph node status
1 90 30.80 303.7 0.0260 0.0980 128.60 5.40 0.18
2 65 47.00 409.2 0.0150 0.1260 119.72 2.80 0.17
Histology
Ductal 87 63.40 384.1 0.0210 0.0110 119.32 4.64 0.17
Lobular 16 45.90 262.5 0.0160 0.0094 121.64 4.34 0.16
CYP19, aromatase; STS, steroid sulfatase; HSD1, 17β-hydroxysteroid dehydrogenase I; HSD2, 17β-hydroxysteroid dehydrogenase II; EST,
oestradiol sulfotransferase; ERα, oestrogen receptor α; ERβ, oestrogen receptor β. *P < 0.01 (stage III versus stage I). **P < 0.01 (tumour
category 3 and 4 versus tumour category 1 and 2). ***P < 0.05 (tumour category 3 and 4 versus tumour category 1 and 2).
in those patients with TKAT 1 and TKAT 2 (P < 0.01)
(Table 3) and with higher stage of the disease (P < 0.01).
mRNA expression of CYP19 aromatase
A considerable difference in the expression of CYP19 was
observed. Twenty-five per cent of the tumours had no
expression of aromatase at all, and 23% had overexpres-
sion of the transcript (50–800 CYP19 mRNA amol/mg
RNA). A surprisingly high fraction of postmenopausal
women (25%, in contrast to only 5% among pre-
menopausal women in our study) did not express CYP19
in their tumours. These results are of importance for the
strategies for treatment with aromatase inhibitors in post-
menopausal patients.
A switch from the usual adipose tissue promoter to an
apparently stronger ‘ovary’ promoter has been previously
observed in these samples and was associated with the
levels of mRNA expression (P < 0.0001) [4]. We also
detected an alternative poly A tail in 15 of the tumour
samples. The type of poly A tail was not associated to
either alternative use of promoter, or mRNA levels.
mRNA expression and disease-free survival
The levels of mRNA expression were also analysed as
factors for disease-free survival. Patients with expression
of tumour aromatase (CYP19) had a better prognosis than
patients with no expression of this transcript (P < 0.0005)
(Fig. 3a). Furthermore, patients whose aromatase gene
was using the normal adipose tissue promoter had longer
survival than those patients with a switch of promoters.
Lack of expression of aromatase was by far the strongest
prognostic factor in this material of the predominantly early
stages of breast cancer. High levels of expression of STS
were also strongly correlated with short disease-free sur-
vival (P < 0.03) (Fig. 3b). Expression of ERβ mRNA was a
better prognostic factor than that of ERα in these tumours
(Fig. 3c,d). ErbB2, whose amplification and overexpres-
sion is a well-documented modifier of survival, was also a
strong prognostic factor in our material (P < 0.01) (Fig. 4).
mRNA expression and menopausal status
Given that the biosynthesis of oestradiol and its metabo-
lism are very different in premenopausal and post-
menopausal women, we analysed the differences in the
expression of the enzymes studied according to
menopausal status (see Additional files). While all the
main findings presented in Table 2 were also found in the
postmenopausal group, which was also larger in size,
some of the correlations were lost in the premenopausal
group. Most notably lost was the correlation of mRNA
expression of cyclin D1 with several of the oestradiol syn-
thesising enzymes and EST with STS. Multiple correla-
tions were observed in the postmenopausal group,
suggesting a tighter coregulation of the oestrogen synthe-
sis enzymes at the mRNA level in the tumours of post-
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Figure 2
Clustering analysis of levels of mRNA relative to the median. Two distinct
clusters of the oestrogen receptor (ER)-positive and ER-negative
samples were observed. The mRNA expression of the oestradiol
metabolising enzymes, however, did not follow the expression of the ER
in all cases, leading to the formation of several subclasses of tumours:
grey, ERα+/CYP19–; dark green, ERα+/CYP19+; light green,
ERα+/CYP19–/ERβ–; yellow, ERα–/CYP19+/ERβ–; pink,
ERα–/CYP19+/ERβ+; blue, ERα–/CYP19–/ERβ–.
menopausal breast cancer patients than in those of pre-
menopausal breast cancer patients. Additional experi-
ments will be conducted to address this interesting topic.
Discussion
Endogenous oestradiol is synthesised in the ovarian gran-
ulosa cells of premenopausal breast cancer patients or in
the stromal adipose cells of the breast of postmenopausal
breast cancer patients, and is synthesised in minor quanti-
ties in peripheral tissue. These cells, as well as breast
cancer tissue, express all the necessary enzymes for the
synthesis of oestradiol (CYP17, CYP11a, CYP19 and
HSD), as well as enzymes of its further metabolism such
as EST and oestrogen sulfotransferase. We have con-
ducted a study to absolutely quantify the mRNA levels of
the transcripts of several important proteins in the synthe-
sis of oestradiol: CYP19 (aromatase), HSD1, HSD2,
ERα, ERβ, STS and EST. Two other breast cancer-related
regulators, cyclin D1 (CYCLD1) and ERBB2, have also
been included in the study.
The hierarchical clustering analysis revealed two main
clusters (the ER-positive and ER-negative tumours of the
breast), in concordance with results from large-scale
microarray analysis. The mRNA expression of oestrogen
metabolising genes did not directly follow the expression
of the ER: we observed a cluster of ER-positive tumours
with low (below median) expression of these enzymes, as
well as ER-negative tumours with high expression of
oestradiol synthesising enzymes. This information may
help to further nuance the prediction of response to hor-
monal treatment in addition to ER status.
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Figure 3
Kaplan–Meier analysis of disease-free survival of breast cancer patients dependent on the expression of mRNA coding for oestradiol metabolising
enzymes. (a) CYP19 (aromatase) using the conventional, adipose tissue-specific first exon (curve 1), abnormally using the ovarian-specific first
exon (curve 2), and with the 0-null expression (curve 0). (b) Steroid sulfatase with expression below (curve 1) and above (curve 2) the median. (c)
Oestrogen receptor (ER)α below (curve 1) and above (curve 2) the median. (d) ERβ below (curve 2) and above (curve 1) the median.
Our results of increased levels of EST mRNA were in con-
cordance with metabolic data in vivo showing high con-
centrations of the product of sulfotransferase activity
(oestrone sulfate [E1S]) in tumours of the breast [13,28].
Similar data from fibroadenomas and breast cysts [29]
suggest that oestrone and oestradiol can be converted to
E1S within the breast cysts in vivo at remarkably high
speed. Furthermore, the formation of E1S (EST activity)
was shown to be upregulated by a number of growth
factors, such as the epidermal growth factor, insulin-like
growth factor type 1, and acidic and basic fibroblast
growth factors in the ER-positive MCF7 cells but not in the
ER-negative MDA-MB-231 cells. The cytokines tumour
necrosis factor alpha and interleukin-1b also increase the
sulfate formation in ER-positive cell lines but not in ER-neg-
ative cell lines [30]. We can indirectly confirm this ER
dependence in humans in vivo because the expression of
mRNA of EST in the breast cancer tissue correlated with
the ER expression in our sample material. The amounts of
STS and ERα mRNA seemed to be coregulated in the
present study and in another independent cohort of breast
cancer patients analysed in our laboratory (data not
shown). They also correlated with mRNA levels of HSD1.
This observation possibly reflects that all three enzymes
have a common substrate (oestradiol) and could be under
common regulation depending on the oestradiol levels.
The very low mRNA levels of HSD1 and HSD2 strongly
suggest a post-translational mechanism of protein stabilisa-
tion because high protein expression and metabolic activity
of HSD1 have been previously reported in breast cancer
tissue [31]. It has been shown that the HSD1 activity in the
endometrium is elevated during the secretory phase, as
compared with the level during the proliferative phase, and
that the elevation is in response to progesterone via the
progesterone receptors. GATA-3 responsive sequences
have been identified in the 5′ flanking regulatory area of
HSD1 [32]. Comparing patterns of gene expression in
cells with or without expression of the ER by the human
cDNA array revealed clustering of a transcription factor
GATA-3 together with ER. This was hypothesised to regu-
late, in association with the ER, genes critical to the
hormone-responsive breast cancer phenotype [33]. Spe-
cific HSD oxidation–reduction activity has been discussed
to play a role in the transition from hormone dependence to
hormone independence of breast cancer [34].
Expression of STS has previously been shown to be a
strong prognostic factor for disease-free survival in breast
cancer [5,13] and in ovarian cell adenocarcinoma [35].
The steroid sulfatase is an important target for the devel-
opment of new drugs for the treatment of endocrine-
dependent breast cancers. One such compound,
2 methoxyoestrone-3-O-sulfamate, was shown to inhibit
the growth of MCF-7 cells by causing arrest in the G(2)/M
phase and apoptosis [36]. Previous analysis has shown a
strong inverse relationship between the length of the
disease-free interval and the plasma levels of E1S and the
ratios of E2/E1 and E1S/E1 in postmenopausal patients
with recurrent disease [37].
The previously reported high correlation of the expression
of CYP19 (aromatase) mRNA and the switch from the
adipose tissue-specific promoter to the ovary-specific pro-
moter was confirmed in this new independent measure-
ment [4]. Furthermore, in the present study the alternative
usage of exon 1 was also associated with shorter disease-
free survival. However, the patients with worse prognosis
had no expression of CYP19 mRNA at all. This is a some-
what paradoxical result since the present data and our
previous data [4] suggest that, in the course of the
disease, a switch of promoter occurs and results in higher
expression levels. The process, however, may occur in a
given time frame of the disease on the way to hormone-
independent breast cancer.
The poor prognosis of patients with null expression of aro-
matase may also reflect prior treatment exposures of the
patients. This is a consecutive series of patients, predomi-
nantly stage I and stage II, who had received a standard
treatment of tamoxifen. Those patients who responded
poorly were offered treatment with an aromatase inhibitor.
We have no exhaustive data on treatment response in
order to verify whether patients with null aromatase
expression in their tumour respond poorly to such stan-
dard therapeutic procedure. Further studies designed to
particularly address treatment response may be neces-
sary. A recent study showed that failure of the antitumour
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Figure 4
Disease-free survival of breast cancer patients as a function of mRNA
expression of ERBB2 below (curve 1) and above (curve 2) the median.
P = 0.011.
activity of tamoxifen in patients with breast cancer is actu-
ally determined by both the levels of and the interaction
between the ER coactivator amplified in breast cancer-1
(AIB1) and the epidermal growth factor-related protein
human epidermal receptor (HER, coded by ERBB2) [38].
Members of the HER family are attractive therapeutic
targets because they are overexpressed and/or deregu-
lated in many solid tumours. Activation of HER1/epidermal
growth factor receptor mediated through ligand binding
triggers a network of signalling processes that promote
tumour cell proliferation, migration, adhesion and angio-
genesis, and that decrease apoptosis. Various
approaches are being investigated to target members of
the HER family, particularly HER1/epidermal growth factor
receptor and HER2 (ERRB2).
Conclusion
Expression studies of tens of thousands of transcripts give
exciting possibilities to draw molecular portraits of tumours
within a given range of expression levels, but they are less
informative for the absolute amounts of single transcripts.
Our results complement these data by providing absolute
quantitative analysis of physiologically important genes with
very low expression levels, such as ERβ and the hydroxys-
teroid dehydrogenases, which remain ‘invisible’ by the
high-density hybridisation arrays. These results also point
to the importance of CYP19 (aromatase) and the enzymes
regulating the oestrone sulfate metabolism as factors of
disease-free survival in breast cancer, in addition to well-
known factors such as the ER and ERBB2.
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